Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $34 from $32 and keeps a Buy rating on the shares. The firm sees meaningful potential upside for the shares with two near-term FDA action dates for Travere. Citi upped the company’s estimates to reflect continued demand growth for Filspari in immunoglobulin A nephropathy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
- Travere Therapeutics Earnings Call Highlights FILSPARI Success
- Travere Therapeutics price target raised to $31 from $30 at Scotiabank
- Travere Therapeutics price target raised to $32 from $30 at Wedbush
- Travere Therapeutics Reports Strong Q2 2025 Growth